Pfizer's Covid-19 Product Sales Continue to Drop — Market Talk

What happened

Pfizer's Covid-19 product sales continued to fall. Paxlovid sales dropped 63% in the third quarter on fewer Covid-19 infections in the U.S. and abroad, while Comirnaty sales fell 29%, partly due to narrower U.S. vaccine recommendations. Pfizer is working to offset the pressure by developing and acquiring new products.

Confirmed

Global impact / market context

Paxlovid and Comirnaty were major revenue sources during the pandemic, so falling sales shrink Pfizer's total revenue and pressure profits. Developing and buying new products costs money and takes time, meaning the company must replace lost sales before earnings growth stalls and investors reassess its value.

Analyst inference

Investors are weighing Pfizer's shrinking Covid-19 revenue against its pipeline of new medicines and acquisitions. The 63% and 29% declines show demand fading faster than some may expect, so attention shifts to whether new products can replace that lost revenue and support the share price.

Analyst inference

What to watch

1. Future quarterly reports will show whether Paxlovid and Comirnaty sales keep falling at similar rates and how much revenue they still contribute to Pfizer's total. Confirmed
2. Watch for announcements about new products Pfizer develops or acquires, since management says these efforts aim to offset the pressure from declining Covid-19 sales. Proposed
3. Track U.S. vaccine recommendations and Covid-19 infection levels, because narrower guidance and fewer infections directly reduced demand for Comirnaty and Paxlovid in the quarter. Analyst inference

Evidence

• Original source link unavailable